Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases

29 Jan 2022

Abstract excerpt

Over the past decade, Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors have arisen as a novel and promising targeted therapy for breast cancer gene (BRCA)-mutated ovarian and breast cancer patients. Therapies targeting the enzyme, PARP-1, have since established their place as maintenance drugs for cancer. Here, we present existing evidence that implicates PARP-1 as a player in the development and progression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to PARP inhibition in cancer therapy
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35158955
DOI: 10.3390/cancers14030687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating DiseasesPMID 35158955Read ↗

Therapeutic Potentials of Poly (ADP‐Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept RevisitingSemantic proximity Read ↗

Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunitiesSemantic proximity Read ↗

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.Semantic proximity Read ↗

PARP-1 deregulation in multiple sclerosisSemantic proximity Read ↗

Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer DiseasesSemantic proximity Read ↗

Pharmacologic inhibition of MIF nuclease: A new treatment paradigm to treat cell deathSemantic proximity Read ↗

PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to AchieveSemantic proximity Read ↗

PARP-1 Deficiency Increases the Severity of Disease in a Mouse Model of Multiple SclerosisSemantic proximity Read ↗

PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesSemantic proximity Read ↗

Two cases of proteasome inhibitors related thrombotic microangiopathies and literature reviewSemantic proximity Read ↗

The Role of Poly(ADP‐ribose) Polymerase‐1 in Rheumatoid ArthritisSemantic proximity Read ↗

Pleiotropic Cellular Functions of PARP1 in Longevity and Aging: Genome Maintenance Meets InflammationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.